• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用Duett血管封闭装置的欧洲多中心注册研究最终报告。

Final report of the European multi-center registry using the Duett vascular sealing device.

作者信息

Silber S, Tofte A J, Kjellevand T O, Grube E, Gershony G

机构信息

Dr. Müller Hospital, Munich, Germany.

出版信息

Herz. 1999 Dec;24(8):620-3. doi: 10.1007/BF03044486.

DOI:10.1007/BF03044486
PMID:10652675
Abstract

Duett, a novel vascular sealing device, was first clinically used in July 1997. A European multi-center registry was established to evaluate the safety and procedural success of the Duett sealing device in a broad range of patients undergoing diagnostic or interventional endovascular procedures. At 25 European sites 1587 patients were enrolled. All patients (> or = 18 years) must have given informed consent for the use of the sealing device after a diagnostic and/or interventional endovascular procedure performed via a femoral arterial approach. Standard length (< or = 10 cm) 5 to 9 F introducer sheaths had to be used. An ACT of < or = 400 s, and any approved GP IIb/IIIa platelet receptor antagonist was permitted. Successful deployment could be achieved in 96.2% (1526/1587 patients) with complete hemostasis within 2 to 5 minutes in over 95% of the patients. The complication-free rate was 96.4%. Arterial occlusions were rare (4 patients) and successfully treated with surgical repair in 1 and with thrombolysis in 3 patients. Pseudoaneurysms occurred in 34 patients, the majority (30/34) were successfully treated with ultrasound-guided compression or resolved spontaneously. The total rate of major complications was 2.6% (41/1587). The final results of the European registry demonstrate that the Duett sealing device can be used with a high procedural success following diagnostic and interventional endovascular procedures. The incidence of major complications is low and comparable to all other approved vascular closure devices and manual compression. CE-mark certification was approved at the end of 1998.

摘要

Duett是一种新型血管封堵装置,于1997年7月首次应用于临床。欧洲建立了一个多中心注册研究,以评估Duett封堵装置在接受诊断性或介入性血管内手术的广泛患者中的安全性和手术成功率。在欧洲的25个中心招募了1587例患者。所有患者(≥18岁)在经股动脉途径进行诊断性和/或介入性血管内手术后,必须已签署使用封堵装置的知情同意书。必须使用标准长度(≤10 cm)的5至9F导入鞘。激活凝血时间(ACT)≤400秒,允许使用任何已获批准的GP IIb/IIIa血小板受体拮抗剂。96.2%(1526/1587例患者)实现了成功置入,超过95%的患者在2至5分钟内实现了完全止血。无并发症发生率为96.4%。动脉闭塞很少见(4例患者),1例通过手术修复成功治疗,3例通过溶栓成功治疗。34例患者发生假性动脉瘤,大多数(30/34)通过超声引导压迫成功治疗或自行消退。主要并发症的总发生率为2.6%(41/1587)。欧洲注册研究的最终结果表明,Duett封堵装置在诊断性和介入性血管内手术后使用时手术成功率很高。主要并发症的发生率很低,与所有其他已获批准的血管闭合装置和手动压迫相当。1998年底获得了CE标志认证。

相似文献

1
Final report of the European multi-center registry using the Duett vascular sealing device.使用Duett血管封闭装置的欧洲多中心注册研究最终报告。
Herz. 1999 Dec;24(8):620-3. doi: 10.1007/BF03044486.
2
Impact of the Duett sealing device on quality of life and hospitalization costs for coronary diagnostic and interventional procedures: Results from the Study of Economic and Quality of Life substudy of the SEAL trial.Duett密封装置对冠状动脉诊断和介入手术患者生活质量及住院费用的影响:SEAL试验经济与生活质量子研究结果
Am Heart J. 2001 Dec;142(6):982-8. doi: 10.1067/mhj.2001.118742.
3
Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: initial U.S. feasibility trial using the Duett vascular closure device.
Catheter Cardiovasc Interv. 2000 May;50(1):96-102. doi: 10.1002/(sici)1522-726x(200005)50:1<96::aid-ccd21>3.0.co;2-v.
4
Assessment of the safety and efficacy of the DUETT vascular hemostasis device: final results of the safe and effective vascular hemostasis (SEAL) trial.DUETT血管止血装置的安全性和有效性评估:安全有效的血管止血(SEAL)试验的最终结果。
Am Heart J. 2002 Apr;143(4):612-9. doi: 10.1067/mhj.2002.121464.
5
[Hemostatic closure of arterial puncture site using Angio-Seal after diagnostic heart catheterization or coronary intervention].
Herz. 1999 Dec;24(8):607-13. doi: 10.1007/BF03044484.
6
Arterial access site closure with a novel sealing device: Duett.使用新型封堵装置(Duett)封闭动脉穿刺部位
Vasc Surg. 2001 May-Jun;35(3):199-201. doi: 10.1177/153857440103500306.
7
Treatment of acute lower limb ischemia following the use of the Duett sealing device: report of three cases and review of the literature.使用Duett封堵装置后急性下肢缺血的治疗:三例报告及文献复习
Cardiovasc Intervent Radiol. 2004 May-Jun;27(3):268-70. doi: 10.1007/s00270-003-0155-1.
8
Systematic Review of Randomized Controlled Trials Comparing Manual Compression to Vascular Closure Devices for Diagnostic and Therapeutic Arterial Procedures.比较手动压迫与血管闭合装置用于诊断和治疗性动脉手术的随机对照试验的系统评价
Surg Technol Int. 2015 Nov;27:32-44.
9
Arterial hemostasis using the Duett sealing device.
Tech Vasc Interv Radiol. 2003 Jun;6(2):85-91. doi: 10.1053/tvir.2003.36445.
10
[10 years of arterial closure devices: a critical analysis of their use after PTCA].[动脉闭合装置应用10年:对其在经皮冠状动脉腔内血管成形术后应用的批判性分析]
Z Kardiol. 2000 May;89(5):383-9. doi: 10.1007/s003920050502.

本文引用的文献

1
Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: initial U.S. feasibility trial using the Duett vascular closure device.
Catheter Cardiovasc Interv. 2000 May;50(1):96-102. doi: 10.1002/(sici)1522-726x(200005)50:1<96::aid-ccd21>3.0.co;2-v.
2
Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device.导管插入术后动脉穿刺部位的管理:评估一种缝线介导的闭合装置。
Am J Cardiol. 1999 Jun 15;83(12):1658-63. doi: 10.1016/s0002-9149(99)00174-5.
3
Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro).在需要使用阿昔单抗(ReoPro)的经导管冠状动脉介入治疗中,血管封堵装置(VasoSeal和Perclose)与手动辅助压迫(Femostop)的应用比较
Catheter Cardiovasc Interv. 1999 Jun;47(2):143-7; discussion 148. doi: 10.1002/(SICI)1522-726X(199906)47:2<143::AID-CCD1>3.0.CO;2-M.
4
A novel vascular sealing device for closure of percutaneous arterial access sites.一种用于闭合经皮动脉穿刺部位的新型血管封闭装置。
Am J Cardiol. 1999 Apr 15;83(8):1248-52. doi: 10.1016/s0002-9149(99)00067-3.
5
Novel vascular sealing device for closure of percutaneous vascular access sites.用于闭合经皮血管穿刺部位的新型血管封闭装置。
Cathet Cardiovasc Diagn. 1998 Sep;45(1):82-8; discussion 90-1. doi: 10.1002/(sici)1097-0304(199809)45:1<82::aid-ccd19>3.0.co;2-n.
6
Vasoseal hemostasis following coronary interventions with Abciximab.
Cathet Cardiovasc Diagn. 1998 Aug;44(4):405-6. doi: 10.1002/(sici)1097-0304(199808)44:4<405::aid-ccd7>3.0.co;2-8.
7
Improved clinical effectiveness with a collagen vascular hemostasis device for shortened immobilization time following diagnostic angiography and percutaneous transluminal coronary angioplasty.使用胶原蛋白血管止血装置提高临床疗效,缩短诊断性血管造影和经皮腔内冠状动脉成形术后的制动时间。
Am J Cardiol. 1998 Jun 15;81(12):1502-5. doi: 10.1016/s0002-9149(98)00221-5.
8
Usefulness of collagen plugging with VasoSeal after PTCA as compared to manual compression with identical sheath dwell times.
Cathet Cardiovasc Diagn. 1998 Apr;43(4):421-7. doi: 10.1002/(sici)1097-0304(199804)43:4<421::aid-ccd13>3.0.co;2-m.
9
[Accidental occlusion of the common femoral artery after Angio-Seal-application].[应用血管封堵器后股总动脉意外闭塞]
Z Kardiol. 1998 Jan;87(1):51-5. doi: 10.1007/s003920050155.
10
Groin complications associated with collagen plug closure of femoral arterial puncture sites in anticoagulated patients.抗凝患者股动脉穿刺部位胶原封堵相关的腹股沟并发症
Cathet Cardiovasc Diagn. 1998 Feb;43(2):124-9. doi: 10.1002/(sici)1097-0304(199802)43:2<124::aid-ccd2>3.0.co;2-c.